Compare DBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBI | MOLN |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 164.2M |
| IPO Year | 1991 | 2021 |
| Metric | DBI | MOLN |
|---|---|---|
| Price | $7.26 | $4.21 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $3.75 |
| AVG Volume (30 Days) | ★ 1.1M | 5.3K |
| Earning Date | 12-09-2025 | 03-05-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,892,654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.70 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.18 | $3.36 |
| 52 Week High | $8.75 | $5.91 |
| Indicator | DBI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 48.81 |
| Support Level | $7.64 | $4.09 |
| Resistance Level | $8.35 | $4.31 |
| Average True Range (ATR) | 0.54 | 0.16 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 23.33 | 30.78 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.